

Health Care Provider referrals to Monoclonal Antibody Infusions

- Monoclonal antibodies (mAbs) directly neutralize the COVID-19 virus and are intended to prevent the progression of disease
- mAbs are likely to be most beneficial if given to patients early in symptom progression
- Product delivered via single IV infusion administration
- Early evidence suggest promise of mAb products in **outpatient** settings to **reduce hospitalization**

Process to refer your patients

1. Review patient eligibility criteria

for patients with mild-moderate symptoms. Full criteria listed by FDA ([Bamlanivimab](#), [Casirivimab and Imdevimab](#)).

2. Perform a COVID-19 PCR or Point-of-Care Rapid Antigen Test

(POC Antigen Tests can be supplied by MDH: complete this [form](#) if interested).

3. Refer your positive patients to a partnering infusion site* ASAP

to start treatment within 10 days of onset of symptoms.

Option 1 (Preferred)

Send e-Referral via the CRISP Unified Landing Page ([Starter guide: pp. 1-7, 25-35](#))

OR

Option 2

Complete referral form ([link](#) at top) and submit directly to infusion site

Adult Eligibility Criteria

At least 1 of the following:

1. BMI ≥ 35 ;
2. Chronic kidney disease;
3. Diabetes;
4. Immunosuppressive disease;
5. Receiving immunosuppressive treatment;
6. Age ≥ 65 years; OR
7. Age ≥ 55 years AND have any of the following:
 - Cardiovascular disease
 - Hypertension
 - COPD/other chronic respiratory disease

* As of 1/22/21, sites accepting CRISP e-Referrals are as follows:

- Adventist-Takoma Park
- Atlantic General
- MedStar Health
- Meritus Health
- TidalHealth Peninsula Regional
- UMPC

Baltimore Convention Center Field Hospital (does not accept CRISP e-Referrals, use this [referral site](#)); Hatzalah of Baltimore (CRISP e-Referral not live yet)